Insights into the Rare-Ultra Orphan market & the challenges for manufacturers, providers, payers, pharmacies, and patients | NASP
Rare diseases affect nearly 10% of the US population and transformative changes to research and development, as well as modernized regulatory pathways, have accelerated the entry of orphan drugs to the market. This uptick has necessitated discussions on how best to manage these conditions to ensure the right therapy is provided to the right patient at the right time. This episode is a first step in creating an open and transparent dialogue on the challenges faced by insurers in a resource constrained healthcare environment. As the focus will offer listeners a view of the latest trends in rare disease / orphan drug market access, assessing current payer perspectives, and offering insights and potential implications of the management of rare disease and orphan drugs. By highlighting the key issues and opportunities, we hope that payers, providers, patients, and biopharmaceutical manufacturers will bridge the access gaps and ensure patients can receive medically necessary therapies to ultimately improve patient outcomes.
You May Also Like

Israel Today: Ongoing War Report
Israel Today: Ongoing War Report

The Epstein Chronicles
Bobby Capucci

Le journal d'Europe 1
Europe 1

Bloomberg News Now
Bloomberg

Brian Kilmeade Show
FOX News Podcasts

Durham News Today | 2 Min News | The Daily News Now!
The Daily News Now!

The Situation Room with Wolf Blitzer and Pamela Brown
CNN Podcasts

Ranch It Up Radio Show & Podcast
Jeff ”Tigger” Erhardt & Rebecca ”BEC” Wanner, Tigger & BEC

Armstrong & Getty On Demand
iHeartPodcasts

Aristegui Noticias Podcast
Sonoro, Aristegui
Community discussion